John Marquez, PA
Medical · Englewood, CONPI 1023153723
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,975 of the $10,545 with a category attached, or 85.1%. 35 manufacturers reported payments, led by Gilead at 39.9% of the total. Among medical clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 415 payments — averaging $25.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$4K
- Viiv Healthcare Company$2K
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$398
- AstraZeneca$355
- Lilly USA, LLC$298
- plus $2K from 29 others
What the payments were for
- Consulting fees$1,57015%
- Food & beverage$8,97585%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 84 | $4,204 |
| Viiv Healthcare Company | 70 | $1,771 |
| AbbVie(2 entities) | 92 | $1,604 |
| Otsuka America Pharmaceutical, Inc. | 26 | $398 |
| AstraZeneca | 21 | $355 |
| Lilly USA, LLC | 18 | $298 |
| Pfizer | 18 | $278 |
| Johnson & Johnson | 12 | $195 |
| Merck | 6 | $173 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $166 |
| Vanda Pharmaceuticals Inc. | 7 | $130 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $112 |
| Exact Sciences | 5 | $102 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $82 |
| Astellas Pharma US Inc | 3 | $71 |
| Idorsia Pharmaceuticals US Inc | 4 | $63 |
| Aimmune Therapeutics, Inc. | 4 | $62 |
| Genentech USA, Inc. | 4 | $58 |
| Lundbeck LLC | 2 | $53 |
| Novo Nordisk | 2 | $50 |
| Exeltis, USA Inc. | 1 | $33 |
| Nestle Healthcare Nutrition Inc. | 2 | $31 |
| Boston Scientific | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Alkermes, Inc. | 1 | $24 |
| Novartis | 1 | $24 |
| Phadia US Inc. | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Organon | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Philips North America LLC | 1 | $15 |
| Inspire Medical Systems, Inc. | 1 | $14 |
| IBSA Pharma Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,545 in reported general payments places this provider in the 95th percentile of 766 medical providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 46 | $35,294 |
| OzempicSemaglutide | 24 | $30,968 |
| EliquisApixaban | 36 | $30,543 |
| XareltoRivaroxaban | 39 | $20,408 |
| RexultiBrexpiprazole | 13 | $17,015 |
| MounjaroTirzepatide | 14 | $16,373 |
| Spiriva RespimatTiotropium Bromide | 15 | $8,670 |
| MyrbetriqMirabegron | 22 | $5,935 |
| Memantine Hcl ErMemantine Hcl | 69 | $5,823 |
| Fenofibrate | 12 | $5,706 |
| JardianceEmpagliflozin | 12 | $5,448 |
| Lacosamide | 24 | $4,434 |
| DuleraMometasone/Formoterol | 13 | $4,378 |
| Oxycodone Hcl | 126 | $2,608 |
| Aripiprazole | 17 | $2,075 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,604 | $35,29446 claims |
| Novo NordiskOzempic | $50 | $30,96824 claims |
| PfizerEliquis | $278 | $30,54336 claims |
| Johnson & JohnsonXarelto | $195 | $20,40839 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $398 | $17,01513 claims |
| Lilly USA, LLCMounjaro | $298 | $16,37314 claims |
| Astellas Pharma US IncMyrbetriq | $71 | $5,93522 claims |
| MerckDulera | $173 | $4,37813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 766 medical providers in Colorado.
Other medical in Englewood
- Neelam GalaEnglewood$18K
- Olivia FrankeEnglewood$9K
- Staeci LeeEnglewood$7K
- Christen KutzColorado Springs$610K
- Amanda MixonFort Collins$342K
- Kristin RyggColorado Springs$255K
- Jordan MastDenver$247K
- John NovakAurora$173K
- Michelle BarnettColorado Springs$138K
- Michael JacobsonFort Collins$131K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.